Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Long-Term Prospective Study of Recurrent Venous Thromboembolism in Patients Younger than 50 Years

García-Fuster M.-J.a · Forner M.-J.a · Fernández C.a · Gil J.b · Vaya A.c · Maldonado L.b

Author affiliations

aService of Internal Medicine and bService of Radiology, Hospital Clínico Universitario, cThrombosis and Haemostasis Unit, Hospital La Fe, Valencia, Spain

Corresponding Author

María-José García-Fuster, MD

Service of Internal Medicine, Hospital Clínico Universitario

Avda. Blasco Ibáñez 10

ES–46010 Valencia (Spain)

Tel./Fax +34 96 3862647, E-Mail garciafuster_mjo@gva.es

Related Articles for ""

Pathophysiol Haemos Thromb 2005;34:6–12

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Long-term incidence of recurrent venous thromboembolism (VTE) in patients younger than 50 years, not affected by a malignancy or chronic diseases, are poorly characterized. After the initial episode of VTE and cessation of oral anticoagulation, 98 patients, mean age 32.2 ± 9.2 years were followed for a median of 117 months (range 6–165). Congenital risk factors for VTE were present in 36% of patients, acquired persistent (positive antiphospholipid antibodies during the whole follow-up) in 19%, and acquired transitory in 44%. Thirty episodes of recurrent VTE were documented. The cumulative incidence of VTE after 1 year of follow-up was 5.1%, 9.8% after 2 years, 14% after 4 years, and 34.2% after 8 years. In the univariate analysis, the relative risk of recurrent VTE was 2.66 [95% confidence interval (CI) 1.03–6.90] for congenital risk factors, 4.97 (95% CI 1.75–14.0) for persistent acquired (antiphospholipid antibodies), 2.64 (95% CI 1.23–5.66) for male gender and 2.27(1.00–5.15) for body mass index >30 kg/m2. In the multivariate analysis, male gender [hazard ratio (HR) 4.23, 95% CI 1.88–9.77) the presence of congenital factors (HR 3.28, 95% CI 1.25–8.63) and acquired persistent factors (HR 8.50, 95% CI 2.84–25.50) were independent risk factors for recurrent VTE. In patients under 50 years of age without malignancy or underlying chronic disease, hospitalized for an acute thromboembolic event, the presence of antiphospholipid antibodies, congenital defects of coagulation, male sex, and obesity were risk factors for recurrent VTE. These data raise the possibility that selected patients with VTE may require prolonged anticoagulation to prevent recurrent disease.

© 2005 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: April 18, 2005
Accepted: July 19, 2005
Published online: November 18, 2005
Issue release date: November 2005

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 2

ISSN: 1424-8832 (Print)
eISSN: 1424-8840 (Online)

For additional information: http://www.karger.com/PHT

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.